Safety, Tolerability, and Long-Term Clinical Outcomes of an IL-15 analogue (N-803) Admixed with Bacillus Calmette-Guérin (BCG) for the Treatment of Bladder Cancer

Intravesical BCG is active against non-muscle invasive bladder cancer (NMIBC), but bladder cancer will recur and even progress in a significant number of patients. To improve the response rate, N-803, an IL-15 superagonist was administered in combination with BCG. To evaluate the safety and efficacy...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncoimmunology
Autors principals: Rosser, Charles J., Tikhonenkov, Sergei, Nix, Jeffrey W., Chan, Owen T.M., Ianculescu, Irina, Reddy, Sandeep, Soon-Shiong, Patrick
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2021
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8096327/
https://ncbi.nlm.nih.gov/pubmed/33996264
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2021.1912885
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars